The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Integrating immunotherapy and targeted therapy with TACE in uHCC treatment
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, discusses integrating immunotherapy and targeted therapy with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC). Cross-trial comparisons show the EMERALD-1 regimen (NCT03778957) has a comparable safety profile, even with TACE. This regimen offers an additional option for patients with high disease burden seeking aggressive treatment. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Eisai; Ipsen; Roche
Consulting or Advisory Role – AstraZeneca; BMS; Eisai; MSD Oncology; Roche
Research Funding – Eisai; Ipsen
